HeraMED Ltd (ASX: HMD) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

HeraMED Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $5.30 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 353.25 million
Earnings per share -0.017
Dividend per share N/A
Year To Date Return -40.37%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • HeraMED Ltd (ASX: HMD)
    Latest News

    Doctor performing an ultrasound on pregnant woman
    Healthcare Shares

    HeraMED (ASX:HMD) share price tanks despite US healthcare deal

    The HeraMED Ltd (ASX: HMD) share price is tanking today despite signing a pilot deal with US healthcare player

    Read more »

    HMD ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About HeraMED Ltd

    HeraMED Ltd is engaged in developing, connected pregnancy monitoring solutions for home and professional use. It has developed a foetal heartbeat monitor called HeraBEAT which is a medical-grade, clinically-validated, smart and connected Ultrasound Foetal Doppler device predominantly for use by an expectant mother to self-monitor her foetus' heart rate (FHR). It is also focused on the commercialization and deployment of its HeraCARE pregnancy monitoring solution. Geographically, the company generates a majority of its revenue from the United States of America followed by Australia and Israel.

    HMD Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    22 May 2024 $0.01 $0.00 0.00% 1,135,331 $0.01 $0.02 $0.01
    21 May 2024 $0.01 $0.00 0.00% 1,259,520 $0.01 $0.01 $0.01
    20 May 2024 $0.02 $0.00 0.00% 688,828 $0.02 $0.02 $0.02
    17 May 2024 $0.02 $0.00 0.00% 612,838 $0.02 $0.02 $0.02
    16 May 2024 $0.02 $0.00 0.00% 1,078,116 $0.02 $0.02 $0.02
    15 May 2024 $0.02 $0.00 0.00% 952,111 $0.02 $0.02 $0.02
    14 May 2024 $0.02 $0.00 0.00% 3,281,802 $0.02 $0.02 $0.02

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    28 Mar 2024 David Hinton Issued 71,667 $1,433
    Rights issue.
    09 Oct 2023 Ronald (Ron) Weinberger Issued 7,500,000 $465,000
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr David Hinton Non-Executive Director Aug 2018
    Mr Hinton has an career in the information and technology sectors and is currently Chief Financial Officer and Company Secretary of Empired Limited, an IT and software services provider and prior to that Amcom Telecommunications Ltd. Mr Hinton is also a Non-Executive Director of Valo Therapeutics Oy and of the not for profit Auspire The Australia Day Council of Western Australia and a General Committee member of Royal Perth Yacht Club Inc. He is also the Independent Audit Committee member of the Australian Institute of Marine Science.
    Mr Timothy (Tim) Chapman Non-Executive Director Mar 2024
    Mr Chapman has over 20 years experience in financial services, having advised on a myriad of corporate transactions and capital raisings for public and private companies through IPOs, private placements, reverse takeovers as well as many mergers and acquisitions. Tim has spent the last 15 years of his career advising micro and small companies across a range of industries including healthcare and health tech. Specifically Tim has been supporting HeraMED in an advisory capacity as it has transitioned from a R&D hardware business into a software SaaS business addressing the range of challenges within maternity care.
    Ms Anoushka Gungadin Chief Executive OfficerExecutive Director May 2024
    --
    Mr Cameron Jones Chief Financial OfficerCompany Secretary Apr 2024
    -
    Cameron Jones Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited 21,622,855 6.12%
    Altor Capital Management Pty Ltd <Altor Alpha Fund A/C> 13,307,242 3.77%
    Hsbc Custody Nominees (Australia) Limited 12,920,129 3.66%
    Ripperday Pty Ltd 10,457,496 2.96%
    Altshuler Shaham Trusts Ltd <David Groberman A/C> 9,709,170 2.75%
    Altshuler Shaham Trusts Ltd <Tal Slonim A/C> 9,709,170 2.75%
    Freeman Road Pty Ltd <The Avenue A/C> 9,466,690 2.68%
    Ratdog Pty Ltd 8,200,000 2.32%
    S & S Browne Assets Pty Ltd <S & S Browne Investment A/C> 7,596,616 2.15%
    Tamorer Pty Ltd <Wylie Family A/C> 5,409,091 1.53%
    Sobol Capital Pty Ltd <BOC A/C> 4,725,429 1.34%
    Bryntirion Capital 4,565,844 1.29%
    North of the River Investments Pty Ltd 4,498,000 1.27%
    Charlton WA Pty Ltd <Tinamara Super Fund A/C> 4,250,000 1.20%
    Netwealth Investments Limited <Wrap Services A/C> 4,221,398 1.20%
    Loktor Holdings Pty Ltd <Taybird A/C> 4,163,089 1.18%
    Scintilla Strategic Investments Limited 4,000,000 1.13%
    Dr Matthew Farrugia 3,866,711 1.09%
    Dr Aditya Agarwal 3,567,520 1.01%
    Always Holdings Pty Ltd <The Buhagiar S/F A/C> 3,497,163 0.99%

    Profile

    since

    Note